Entera Bio (ENTX) FCF Margin (2021 - 2025)

Entera Bio (ENTX) has reported FCF Margin for 4 consecutive years, with 3361.9% the latest figure, recorded in Q1 2025.

• Quarterly FCF Margin changed N/A year-over-year to 3361.9% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 17802.38% (down 1403387.0% YoY) and the FY2025 annual result came in at 17802.38%, down 1403387.0% from the prior year.
• FCF Margin fell to 3361.9% in Q1 2025 per ENTX's latest filing, from 1792.68% in the prior quarter.
• Over the last five years, FCF Margin for ENTX reached as high as 1478.34% in Q1 2021 and fell as low as 35887.5% in Q3 2022.
• A 4-year average of 6909.31% and a median of 2852.01% in 2024 frame the typical range for FCF Margin.
• The largest YoY upside for FCF Margin was 452231 bps in 2022 against a maximum downside of 3437607 bps in 2022.
• Year by year, FCF Margin stood at 1528.48% in 2021, then sank by 841 bps to 14385.71% in 2022, then surged by 88 bps to 1792.68% in 2024, then tumbled by 88 bps to 3361.9% in 2025.
• According to Business Quant data, FCF Margin over the past three periods registered 3361.9%, 1792.68%, and 5128.57% for Q1 2025, Q4 2024, and Q3 2024 respectively.